Evaluation of tramadol / acetaminophen combination tablets to evaluate the effectiveness of analgesic treatment in cancer patients who had the symptomatic chemotherapy induced peripheral neuropathy.
Phase 2
- Conditions
- Chemotherapy induced peripheral neuropathy
- Registration Number
- JPRN-UMIN000018147
- Lead Sponsor
- Department of Internal Medicine, Medical Oncology, School of Medicine, Kyorin University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1)In taking acetaminophen or tramadol component. 2)Opioids is cotraindicated. 3)Acetaminophen is contraindicated. 4)The patient that antidepressant, an antiepileptic drug, antiarrhythmic, pregabalin, Goshajinkigan were started within four weeks from registration. 5)Peripheral neuropathy induced by diabetes, alcohol and drugs except platinum agents and taxane. 6)Taking selegiline hydrochloride.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umerical rating scale of numbness four weeks later after an internal use of tramadol / acetaminophen combination tablets starts.
- Secondary Outcome Measures
Name Time Method Functional Assessment of Cancer Therapy- Neurotoxicity (FACT-NTX) Neuropathic Pain Symptom Inventory (NPSI) Safety